Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein
Catalog No: HLAG-HP004
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide (accession: P17693-1(HLA-G) & P61769(B2M) &RIIPRHLQL).
Product Details
- Molecular Aliases
- HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS, 100mM L-Arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer is greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-HLA-G Antibody, hFc Tag with the EC50 of 5.8ng/ml determined by ELISA.
Background
HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.
References
- (1) Krijgsman D, Roelands J, Hendrickx W, Bedognetti D, Kuppen PJK. HLA-G: A New Immune Checkpoint in Cancer? Int J Mol Sci. 2020 Jun 25;21(12):4528. doi: 10.3390/ijms21124528. PMID: 32630545; PMCID: PMC7350262.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.